CJC-1295 no DAC + Ipamorelin 20mg

Overview

This vial combines two synthetic peptides studied for growth hormone (GH) secretion: CJC-1295 (no DAC), a GHRH analogue, and Ipamorelin, a selective agonist of the GH secretagogue receptor (ghrelin receptor).

Mechanism of action

CJC-1295 prolongs stimulation of the GH/IGF-1 axis; Ipamorelin triggers GH release selectively, without notable elevation of ACTH, cortisol or prolactin at active doses — unlike other secretagogues.

Research context

In a phase 2 clinical trial (Teichman et al., 2006), a single injection of CJC-1295 produced dose-dependent increases in GH (2 to 10×) and IGF-1 (1.5 to 3×) sustained over several days in healthy adults. Ipamorelin’s selectivity was characterised by Raun et al. (1998).

Quality assurance

• Purity ≥ 99 % verified by HPLC
• Certificate of Analysis (COA) available per batch
• Traceability: unique batch number on every vial

Format & handling

Presentation: lyophilised powder, 20 mg (10 mg + 10 mg) / vial · Reconstitution: bacteriostatic water · Storage: refrigerate the lyophilisate; after reconstitution, keep cold and protected from light.

References

• Teichman SL et al. « Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295… », J Clin Endocrinol Metab, 2006.
• Raun K et al. « Ipamorelin, the first selective growth hormone secretagogue », Eur J Endocrinol, 1998.